48-week (wk) results from two prospective, 96-wk studies investigating the efficacy and safety of brolucizumab vs aflibercept in nAMD
Name
198 - HAWK & HARRIER : Résultats de deux études multicentriques, randomisées, en double insu, sur deux ans, comparant brolucizumab versus aflibercept chez des sujets atteints de DMLA néovasculaire
Name
198 - HAWK & HARRIER : Résultats de deux études multicentriques, randomisées, en double insu, sur deux ans, comparant brolucizumab versus aflibercept chez des sujets atteints de DMLA néovasculaire
Orateurs :
Dr Sam RAZAVI
Résumé
Introduction
Patients et Methodes
Patients were randomized 1:1:1 to brolucizumab 3/6 mg or aflibercept 2 mg (HAWK) or 1:1 to brolucizumab 6 mg or aflibercept 2 mg (HARRIER). After the loading phase, brolucizumab patients received q12w dosing with an option to adjust to q8w based on masked and predetermined disease activity assessments visits
Résultats
Brolucizumab 3 and 6 mg were non-inferior to aflibercept in mean BCVA change. After the loading phase, 57% and 52% of patients on brolucizumab 6 mg were maintained exclusively on q12w dosing in HAWK and HARRIER respectively. The overall ocular /non-ocular adverse event rates of brolucizumab were comparable to aflibercept.
Discussion
Conclusion
Significant visual gains were achieved in nAMD patients with a majority maintained on an exclusive q12w dosing interval immediately after the loading phase until wk 48.